Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Xenon Pharmaceuticals is a biotechnology business based in the US. Xenon Pharmaceuticals shares (XENE) are listed on the NASDAQ and all prices are listed in US Dollars. Xenon Pharmaceuticals employs 149 staff and has a trailing 12-month revenue of around $13.2 million.
Finder Award
SoFi Invest
Finder Award
eToro
Robinhood
| Latest market close | $39.19 |
|---|---|
| 52-week range | $24.94 - $41.39 |
| 50-day moving average | $37.28 |
| 200-day moving average | $34.57 |
| Wall St. target price | $50.67 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-1.56 |
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $39.19 from 2023-02-03
| 1 week (2023-01-31) | 0.26% |
|---|---|
| 1 month (2023-01-06) | 2.43% |
| 3 months (2022-11-07) | 12.71% |
| 6 months (2022-08-05) | 1.87% |
| 1 year (2022-02-03) | N/A |
|---|---|
| 2 years (2021-02-05) | 142.81% |
| 3 years (2020-02-07) | 166.06% |
| 5 years (2018-02-07) | 1,061.19% |
| Revenue TTM | $13.2 million |
|---|---|
| Gross profit TTM | $-57,026,000 |
| Return on assets TTM | -13.3% |
| Return on equity TTM | -22.66% |
| Profit margin | 0% |
| Book value | $12.04 |
| Market capitalisation | $2.4 billion |
TTM: trailing 12 months
We're not expecting Xenon Pharmaceuticals to pay a dividend over the next 12 months.
Over the last 12 months, Xenon Pharmaceuticals's shares have ranged in value from as little as $24.94 up to $41.39. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Xenon Pharmaceuticals's is 1.3634. This would suggest that Xenon Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Xenon Pharmaceuticals Inc. , a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1. 6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other potential indications, including adult focal epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase II clinical trials. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy; and with Flexion Therapeutics, Inc.
Everything we know about the Neuraxis IPO, plus information on how to buy in.
Everything we know about the TXO Energy IPO, plus information on how to buy in.
Everything we know about the Brera IPO, plus information on how to buy in.
What you need to know about investing in the leading indicator for the overall US stock market.
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
Your simple and straightforward guide to ETFs, how they work and the different types available.
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
Everything we know about the SONDORS IPO, plus information on how to buy in.
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.